Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACVR1 | Q04771 | 14/20 | 1.00 |
| ▸ | ACVRL1 | P37023 | 11/20 | 1.00 |
| ▸ | BMPR1B | O00238 | 10/20 | 1.00 |
| ▸ | BMP4 | P12644 | 5/20 | 0.76 |
| ▸ | BMPR1A | P36894 | 5/20 | 0.69 |
| ▸ | ACVR1B | P36896 | 7/20 | 0.67 |
| ▸ | KDR | P35968 | 2/20 | 0.64 |
| ▸ | TGFBR1 | P36897 | 2/20 | 0.64 |
| ▸ | PRKAB1 | Q9Y478 | 2/20 | 0.64 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.54 |
| ▸ | BMPR2 | Q13873 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16134965 | 0.94 | ACVR1 (1.00) | ACVR1ACVRL1BMPR1BBMP4BMPR1A | |
| SCHEMBL17531643 | 0.87 | ACVR1 (0.88) | ACVR1ACVRL1BMPR1BBMP4BMPR1A | |
| SCHEMBL11953448 | 0.86 | BMP4 (1.00) | ACVR1ACVRL1BMPR1BBMP4BMPR1A | |
| SCHEMBL17531630 | 0.83 | ACVRL1 (0.83) | ACVR1ACVRL1BMPR1BBMP4BMPR1A | |
| SCHEMBL16112182 | 0.81 | ACVR1 (1.00) | ACVR1ACVRL1BMPR1BBMP4BMPR1A | |
| SCHEMBL16025969 | 0.80 | ACVR1 (1.00) | ACVR1ACVRL1BMPR1BBMP4BMPR1A | |
| SCHEMBL16112527 | 0.80 | ACVR1 (1.00) | ACVR1ACVRL1BMPR1BBMP4BMPR1A | |
| SCHEMBL16112356 | 0.80 | ACVR1 (0.66) | ACVR1ACVRL1BMPR1BBMP4BMPR1A | |
| SCHEMBL23989036 | 0.80 | ACVR1 (0.72) | ACVR1ACVRL1BMPR1BBMP4BMPR1A | |
| SCHEMBL16111444 | 0.79 | ACVR1 (1.00) | ACVR1ACVRL1BMPR1BBMP4BMPR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230398118-A1 | METHODS OF TREATING CARDIOVASCULAR-RELATED DISEASE | KEROS THERAPEUTICS, INC. | 2023-12-14 | — | — | US | disclosed |
| US-20230398118-A1 | METHODS OF TREATING CARDIOVASCULAR-RELATED DISEASE | KEROS THERAPEUTICS, INC. | 2023-12-14 | — | — | US | disclosed |
| US-20230372390-A1 | METHODS OF TREATING LYMPHOPENIA | KEROS THERAPEUTICS, INC. | 2023-11-23 | — | — | US | disclosed |
| US-20230372390-A1 | METHODS OF TREATING LYMPHOPENIA | KEROS THERAPEUTICS, INC. | 2023-11-23 | — | — | US | disclosed |
| WO-2023081212-A1 | METHODS OF USING ALK2 INHIBITORS | KEROS THERAPEUTICS, INC. (US) | 2023-05-11 | — | — | WO | disclosed |
| US-20220401445-A1 | METHODS OF USING ALK2 INHIBITORS | KEROS THERAPEUTICS, INC. | 2022-12-22 | — | — | US | disclosed |
| WO-2022098821-A1 | METHODS OF TREATING LYMPHOPENIA | KEROS THERAPEUTICS, INC. (US) | 2022-05-12 | — | — | WO | disclosed |
| WO-2022098812-A1 | METHODS OF TREATING IRON OVERLOAD | KEROS THERAPEUTICS, INC. (US) | 2022-05-12 | — | — | WO | disclosed |
| WO-2022099166-A1 | METHODS OF TREATING CARDIOVASCULAR-RELATED DISEASE | KEROS THERAPEUTICS, INC. (US) | 2022-05-12 | — | — | WO | disclosed |
| WO-2021222875-A1 | METHODS OF USING ALK2 INHIBITORS | KEROS THERAPEUTICS, INC. (US) | 2021-11-04 | — | — | WO | disclosed |
| US-20170334918-A1 | BMP Inhibitors and Methods of Use Thereof | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2017-11-23 | — | — | US | disclosed |
| US-9682983-B2 | BMP inhibitors and methods of use thereof | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2017-06-20 | — | — | US | disclosed |
| US-9682983-B2 | BMP inhibitors and methods of use thereof | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2017-06-20 | — | — | US | disclosed |
| US-9682983-B2 | BMP inhibitors and methods of use thereof | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2017-06-20 | — | — | US | disclosed |
| US-20160046633-A1 | BMP INHIBITORS AND METHODS OF USE THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2016-02-18 | — | — | US | disclosed |
| US-20160046633-A1 | BMP INHIBITORS AND METHODS OF USE THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2016-02-18 | — | — | US | disclosed |
| US-20160046633-A1 | BMP INHIBITORS AND METHODS OF USE THEREOF | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2016-02-18 | — | — | US | disclosed |
| EP-2970311-A2 | BMP INHIBITORS AND METHODS OF USE THEREOF | The Brigham and Women's Hospital, Inc. (US) | 2016-01-20 | — | — | EP | disclosed |
| WO-2014160203-A2 | BMP INHIBITORS AND METHODS OF USE THEREOF | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2014-10-02 | — | — | WO | disclosed |
| WO-2014160203-A2 | BMP INHIBITORS AND METHODS OF USE THEREOF | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2014-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220401445-A1 | METHODS OF USING ALK2 INHIBITORS | ALK, ACVR2A, ACVR1 | ACVR1 3/4885ACVRL1 6/4885BMPR1B 33/4885 |
| US-20160046633-A1 | BMP INHIBITORS AND METHODS OF USE THEREOF | BMP1, BMPR2, BMP2 | ACVR1 13/4885ACVRL1 14/4885BMPR1B 4/4885 |
| US-20230398118-A1 | METHODS OF TREATING CARDIOVASCULAR-RELATED DISEASE | BMPR2, BMP1, BMP2 | ACVR1 13/4885ACVRL1 22/4885BMPR1B 5/4885 |
| US-20170334918-A1 | BMP Inhibitors and Methods of Use Thereof | BMP1, BMPR2, BMP2 | ACVR1 13/4885ACVRL1 14/4885BMPR1B 4/4885 |
| US-20230372390-A1 | METHODS OF TREATING LYMPHOPENIA | HAMP, BMPR2, BMP2 | ACVR1 16/4885ACVRL1 28/4885BMPR1B 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.